Other Stories

U.S. FDA approves emergency authorization of convalescent plasma to treat COVID-19 patients Updated: 2020-08-24 10:09:16 KST

The U.S. Food and Drug Administration has approved emergency authorization of convalescent plasma as a potential treatment for COVID-19.
President Trump announced on Sunday that this major green light from the government could save countless lives in the future.

"The FDA has issued an emergency use authorization, and that's such a powerful term emergency use authorization for a treatment known as convalescent plasma."

The plasma treatment involves using antibodies from the blood of COVID-19 survivors.
Until now, more than 70-thousand Americans have already received the treatment.
However, it is still not clear what effect the decision will have for convalescent plasma treatment because of inconclusive evidence on its effectiveness and the appropriate dosage.
In addition, the FDA's commissioner, Stephen Hahn said in the briefing on Sunday that the treatment still needs to undergo randomized clinical trials to decide its safety and effectiveness.
As of Monday, the U.S. has had a total of more than 5 million COVID-19 cases and 170-thousand deaths.
Choi Won-jong, Arirang News.
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.